Annual Total Liabilities
$39.00 M
-$12.73 M-24.61%
December 31, 2023
Summary
- As of February 6, 2025, LCTX annual total liabilities is $39.00 million, with the most recent change of -$12.73 million (-24.61%) on December 31, 2023.
- During the last 3 years, LCTX annual total liabilities has risen by +$26.17 million (+204.13%).
- LCTX annual total liabilities is now -53.38% below its all-time high of $83.65 million, reached on December 31, 2021.
Performance
LCTX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$31.80 M
-$4.13 M-11.49%
September 30, 2024
Summary
- As of February 6, 2025, LCTX quarterly total liabilities is $31.80 million, with the most recent change of -$4.13 million (-11.49%) on September 30, 2024.
- Over the past year, LCTX quarterly total liabilities has dropped by -$7.69 million (-19.48%).
- LCTX quarterly total liabilities is now -61.98% below its all-time high of $83.65 million, reached on December 31, 2021.
Performance
LCTX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
LCTX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.6% | -19.5% |
| 3 y3 years | +204.1% | -40.7% |
| 5 y5 years | +314.2% | +180.0% |
LCTX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -53.4% | at low | -62.0% | at low |
| 5 y | 5-year | -53.4% | +204.1% | -62.0% | +185.1% |
| alltime | all time | -53.4% | >+9999.0% | -62.0% | >+9999.0% |
Lineage Cell Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $31.80 M(-11.5%) |
| Jun 2024 | - | $35.93 M(-4.2%) |
| Mar 2024 | - | $37.49 M(-3.9%) |
| Dec 2023 | $39.00 M(-24.6%) | $39.00 M(-1.3%) |
| Sep 2023 | - | $39.49 M(-2.3%) |
| Jun 2023 | - | $40.43 M(-8.5%) |
| Mar 2023 | - | $44.19 M(-14.6%) |
| Dec 2022 | $51.73 M(-38.2%) | $51.73 M(-3.5%) |
| Sep 2022 | - | $53.59 M(-1.5%) |
| Jun 2022 | - | $54.42 M(-8.2%) |
| Mar 2022 | - | $59.30 M(-29.1%) |
| Dec 2021 | $83.65 M(+552.4%) | $83.65 M(+619.7%) |
| Sep 2021 | - | $11.62 M(+4.2%) |
| Jun 2021 | - | $11.15 M(-1.8%) |
| Mar 2021 | - | $11.36 M(-11.4%) |
| Dec 2020 | $12.82 M(-9.9%) | $12.82 M(-0.7%) |
| Sep 2020 | - | $12.91 M(-10.3%) |
| Jun 2020 | - | $14.39 M(+1.9%) |
| Mar 2020 | - | $14.12 M(-0.8%) |
| Dec 2019 | $14.23 M(+51.2%) | $14.23 M(-18.5%) |
| Sep 2019 | - | $17.46 M(-12.4%) |
| Jun 2019 | - | $19.93 M(-11.3%) |
| Mar 2019 | - | $22.48 M(+138.8%) |
| Dec 2018 | $9.41 M(+4.9%) | $9.41 M(+44.4%) |
| Sep 2018 | - | $6.52 M(-13.1%) |
| Jun 2018 | - | $7.50 M(-5.5%) |
| Mar 2018 | - | $7.94 M(-11.6%) |
| Dec 2017 | $8.98 M(-25.6%) | $8.98 M(-30.3%) |
| Sep 2017 | - | $12.88 M(-15.1%) |
| Jun 2017 | - | $15.17 M(-2.3%) |
| Mar 2017 | - | $15.52 M(+28.6%) |
| Dec 2016 | $12.06 M(-33.8%) | $12.06 M(+6.5%) |
| Sep 2016 | - | $11.33 M(+10.3%) |
| Jun 2016 | - | $10.28 M(-49.9%) |
| Mar 2016 | - | $20.52 M(+12.7%) |
| Dec 2015 | $18.21 M(+49.6%) | $18.21 M(+14.4%) |
| Sep 2015 | - | $15.93 M(+8.6%) |
| Jun 2015 | - | $14.66 M(+20.2%) |
| Mar 2015 | - | $12.19 M(+0.1%) |
| Dec 2014 | $12.18 M(-21.3%) | $12.18 M(-27.1%) |
| Sep 2014 | - | $16.70 M(-13.9%) |
| Jun 2014 | - | $19.40 M(+54.2%) |
| Mar 2014 | - | $12.59 M(-18.6%) |
| Dec 2013 | $15.47 M(+183.6%) | $15.47 M(+182.0%) |
| Sep 2013 | - | $5.49 M(+2.0%) |
| Jun 2013 | - | $5.38 M(+1.2%) |
| Mar 2013 | - | $5.31 M(-2.6%) |
| Dec 2012 | $5.45 M(+24.8%) | $5.45 M(+49.1%) |
| Sep 2012 | - | $3.66 M(-10.5%) |
| Jun 2012 | - | $4.09 M(+29.9%) |
| Mar 2012 | - | $3.15 M(-28.0%) |
| Dec 2011 | $4.37 M(+13.6%) | $4.37 M(+10.4%) |
| Sep 2011 | - | $3.96 M(-13.7%) |
| Jun 2011 | - | $4.59 M(+12.3%) |
| Mar 2011 | - | $4.08 M(+6.2%) |
| Dec 2010 | $3.85 M(+61.2%) | $3.85 M(+61.3%) |
| Sep 2010 | - | $2.38 M(-4.8%) |
| Jun 2010 | - | $2.50 M(+9.6%) |
| Mar 2010 | - | $2.29 M(-4.2%) |
| Dec 2009 | $2.39 M(-55.7%) | $2.39 M(-53.4%) |
| Sep 2009 | - | $5.12 M(-22.6%) |
| Jun 2009 | - | $6.61 M(-0.4%) |
| Mar 2009 | - | $6.64 M(+23.3%) |
| Dec 2008 | $5.38 M | $5.38 M(-7.9%) |
| Sep 2008 | - | $5.85 M(+29.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2008 | - | $4.53 M(+15.8%) |
| Mar 2008 | - | $3.91 M(+21.4%) |
| Dec 2007 | $3.22 M(+28.1%) | $3.22 M(+10.8%) |
| Sep 2007 | - | $2.91 M(+2.4%) |
| Jun 2007 | - | $2.84 M(+3.6%) |
| Mar 2007 | - | $2.74 M(+8.9%) |
| Dec 2006 | $2.52 M(+16.7%) | $2.52 M(+4.8%) |
| Sep 2006 | - | $2.40 M(+1.4%) |
| Jun 2006 | - | $2.37 M(-0.9%) |
| Mar 2006 | - | $2.39 M(+10.7%) |
| Dec 2005 | $2.16 M(+83.2%) | $2.16 M(+28.1%) |
| Sep 2005 | - | $1.68 M(+14.5%) |
| Jun 2005 | - | $1.47 M(+27.3%) |
| Mar 2005 | - | $1.15 M(-1.9%) |
| Dec 2004 | $1.18 M(-66.4%) | $1.18 M(+55.7%) |
| Sep 2004 | - | $755.60 K(-8.7%) |
| Jun 2004 | - | $827.50 K(+42.9%) |
| Mar 2004 | - | $578.90 K(-83.5%) |
| Dec 2003 | $3.50 M(+31.3%) | $3.50 M(+12.0%) |
| Sep 2003 | - | $3.13 M(+4.1%) |
| Jun 2003 | - | $3.00 M(-5.8%) |
| Mar 2003 | - | $3.19 M(+19.5%) |
| Dec 2002 | $2.67 M(+30.7%) | $2.67 M(+14.9%) |
| Sep 2002 | - | $2.32 M(+1.6%) |
| Jun 2002 | - | $2.28 M(+13.4%) |
| Mar 2002 | - | $2.01 M(-1.3%) |
| Dec 2001 | $2.04 M(+467.3%) | $2.04 M(-40.9%) |
| Sep 2001 | - | $3.45 M(+315.6%) |
| Jun 2001 | - | $830.60 K(+508.9%) |
| Mar 2001 | - | $136.40 K(-62.1%) |
| Dec 2000 | $359.70 K(-39.6%) | $359.70 K(+215.8%) |
| Sep 2000 | - | $113.90 K(-63.0%) |
| Jun 2000 | - | $308.20 K(+141.9%) |
| Mar 2000 | - | $127.40 K(-78.6%) |
| Dec 1999 | $595.50 K(+45.4%) | $595.50 K(+19.1%) |
| Sep 1999 | - | $500.00 K(+66.7%) |
| Jun 1999 | - | $300.00 K(-25.0%) |
| Mar 1999 | - | $400.00 K(-20.0%) |
| Dec 1998 | $409.50 K(-31.8%) | - |
| Sep 1998 | - | $500.00 K(-16.7%) |
| Jun 1998 | - | $600.00 K(-25.0%) |
| Jun 1998 | $600.00 K(-66.7%) | - |
| Mar 1998 | - | $800.00 K(-20.0%) |
| Dec 1997 | - | $1.00 M(-37.5%) |
| Sep 1997 | - | $1.60 M(-11.1%) |
| Jun 1997 | $1.80 M(+800.0%) | $1.80 M(+1700.0%) |
| Mar 1997 | - | $100.00 K(-66.7%) |
| Dec 1996 | - | $300.00 K(+200.0%) |
| Sep 1996 | - | $100.00 K(-50.0%) |
| Jun 1996 | $200.00 K(-50.0%) | $200.00 K(+100.0%) |
| Sep 1995 | - | $100.00 K(-75.0%) |
| Jun 1995 | $400.00 K(+300.0%) | $400.00 K(+300.0%) |
| Mar 1995 | - | $100.00 K(0.0%) |
| Dec 1994 | - | $100.00 K(0.0%) |
| Sep 1994 | - | $100.00 K(0.0%) |
| Jun 1994 | $100.00 K(0.0%) | $100.00 K(0.0%) |
| Mar 1994 | - | $100.00 K(0.0%) |
| Dec 1993 | - | $100.00 K(0.0%) |
| Sep 1993 | - | $100.00 K(0.0%) |
| Jun 1993 | $100.00 K(-50.0%) | $100.00 K(0.0%) |
| Mar 1993 | - | $100.00 K(0.0%) |
| Dec 1992 | - | $100.00 K(0.0%) |
| Sep 1992 | - | $100.00 K(-50.0%) |
| Jun 1992 | $200.00 K | $200.00 K(-33.3%) |
| Mar 1992 | - | $300.00 K |
FAQ
- What is Lineage Cell Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual total liabilities year-on-year change?
- What is Lineage Cell Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly total liabilities year-on-year change?
What is Lineage Cell Therapeutics annual total liabilities?
The current annual total liabilities of LCTX is $39.00 M
What is the all time high annual total liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual total liabilities is $83.65 M
What is Lineage Cell Therapeutics annual total liabilities year-on-year change?
Over the past year, LCTX annual total liabilities has changed by -$12.73 M (-24.61%)
What is Lineage Cell Therapeutics quarterly total liabilities?
The current quarterly total liabilities of LCTX is $31.80 M
What is the all time high quarterly total liabilities for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly total liabilities is $83.65 M
What is Lineage Cell Therapeutics quarterly total liabilities year-on-year change?
Over the past year, LCTX quarterly total liabilities has changed by -$7.69 M (-19.48%)